Last updated: September 23, 2026
Rifaximin, marketed in the United States as Xifaxan by Bausch Health’s Salix Pharmaceuticals, is a high-value gastrointestinal drug with annual U.S. sales of roughly $1.2 billion in 2023. Its commercial strength comes from chronic and repeat use in hepatic encephalopathy and irritable bowel syndrome with diarrhea, combined with limited direct generic competition. The principal generic threat is tied to Paragraph IV litigation involving Norwich Pharmaceuticals and patents covering rifaximin compositions and formulations. The leading Orange Book protection is expected to constrain generic entry until approximately 2029, subject to patent challenges, settlements, and regulatory developments.
What is rifaximin and which indications drive its market?
Rifaximin is a minimally absorbed rifamycin antibacterial administered orally. Its low systemic exposure supports use in gastrointestinal conditions where local intestinal activity is commercially and clinically important.
| Indication |
U.S. dosage strength |
FDA status |
Commercial role |
| Hepatic encephalopathy recurrence reduction |
550 mg |
Approved |
Largest chronic-use segment |
| Irritable bowel syndrome with diarrhea |
550 mg |
Approved |
Major outpatient segment |
| Travelers’ diarrhea caused by noninvasive E. coli |
200 mg |
Approved |
Smaller, short-course segment |
| Small intestinal bacterial overgrowth |
Various |
Not specifically FDA-approved |
Off-label demand |
| Crohn’s disease and other gastrointestinal disorders |
Various |
Not specifically FDA-approved |
Limited or investigational use |
The hepatic encephalopathy indication is particularly valuable because patients often receive long-term therapy to reduce recurrence and hospitalizations. IBS-D treatment is generally episodic, but patients can receive repeat courses under the approved regimen.
Xifaxan is commercially differentiated from systemic antibiotics because rifaximin has limited intestinal absorption. The drug’s clinical value is therefore linked to gastrointestinal targeting rather than broad systemic antibacterial activity.
How large is the rifaximin market?
The U.S. market is the economic center of rifaximin sales. Xifaxan generated approximately $1.2 billion in annual revenue for Bausch Health in 2023, based on company reporting and segment disclosures.[1] Salix Pharmaceuticals, which markets Xifaxan, is one of Bausch Health’s most important business units.
The product has several characteristics that support premium pricing:
- Chronic use in hepatic encephalopathy.
- Repeat treatment cycles for IBS-D.
- Limited substitutability in the approved indications.
- High cost relative to older alternatives such as lactulose.
- Extensive physician familiarity and guideline adoption.
- Regulatory and patent barriers that have delayed generic competition.
Bausch does not generally report rifaximin revenue as a separate public company segment in every quarterly disclosure. Reported Salix performance, prescription trends, price increases, and product-level commentary must therefore be combined to estimate the product’s trajectory.
Rifaximin revenue trajectory
| Period |
Approximate commercial position |
Main driver |
| 2015-2019 |
Rapid expansion |
Growth in hepatic encephalopathy and IBS-D |
| 2020 |
Temporary disruption |
Reduced travel-related and outpatient activity during the pandemic |
| 2021-2023 |
Recovery and expansion |
Chronic hepatic encephalopathy demand and IBS-D recovery |
| 2024 onward |
Mature growth asset |
Price, volume, repeat treatment, and protection from generic entry |
| 2029 onward |
Principal risk window |
Potential generic or authorized-generic competition |
The travelers’ diarrhea business is structurally smaller and more exposed to travel patterns. Hepatic encephalopathy has the strongest recurring-revenue profile because patients may remain on therapy for extended periods.
When does rifaximin lose exclusivity?
The effective U.S. loss-of-exclusivity date is expected to depend on the outcome of patent litigation and the scope of Orange Book-listed patents. The principal commercial protection has generally extended into 2029.
FDA regulatory exclusivity is not the main barrier to competition. The current commercial moat is based primarily on patents, brand prescribing, manufacturing complexity, and the clinical evidence supporting approved uses.
Rifaximin exclusivity timeline
| Milestone |
Timing |
Market effect |
| FDA approval of Xifaxan for travelers’ diarrhea |
2004 |
Established initial U.S. market |
| Hepatic encephalopathy approval |
2010 |
Created the largest chronic-use opportunity |
| IBS-D approval |
2015 |
Added a major repeat-treatment population |
| Norwich ANDA litigation |
2019 onward |
Tested key formulation and composition patents |
| Federal Circuit decision involving Norwich |
2023 |
Preserved major patent barriers |
| Earliest practical generic-entry window |
Approximately 2029 |
Depends on patent outcomes and settlement terms |
The 2029 estimate should be treated as the principal market reference point rather than a guaranteed launch date. Patent-term adjustments, pediatric exclusivity, later-issued patents, court injunctions, and settlement restrictions can change the date.
What patents protect Xifaxan and rifaximin?
The Xifaxan patent estate includes composition, polymorph, formulation, dosing, and method-of-use claims. The most commercially important disputes have involved patents covering rifaximin products and formulations used for approved gastrointestinal indications.
Key rifaximin patent litigation
Norwich Pharmaceuticals sought FDA approval for a rifaximin product through an abbreviated new drug application. Bausch and affiliated entities sued under the Hatch-Waxman framework after receiving Paragraph IV certifications. The litigation focused on patents including U.S. Patent No. 8,309,569 and U.S. Patent No. 10,039,802, among other asserted rights.[2][3]
The Federal Circuit’s 2023 decision preserved Bausch’s ability to block Norwich’s proposed generic product before the relevant patent protection expires. The decision materially reduced the probability of an immediate generic launch and extended the commercial value of the Xifaxan franchise.[3]
| Patent or protection category |
Core subject matter |
Commercial relevance |
| Rifaximin composition patents |
Active ingredient and pharmaceutical forms |
Establish product-level protection |
| Polymorph patents |
Specific crystalline or solid-state forms |
Can restrict API and finished-product design |
| Formulation patents |
Tablets, excipients, dissolution, and stability |
Raise formulation-design and manufacturing barriers |
| Method-of-use patents |
Hepatic encephalopathy, IBS-D, or dosing regimens |
Can support infringement claims after product launch |
| Later-issued patents |
Additional formulation or use claims |
May extend litigation risk beyond earlier patents |
The Orange Book contains multiple listings associated with Xifaxan strengths and indications. The leading patent protection relevant to generic entry has been publicly associated with expiration in approximately 2029, while later-issued or separately listed patents can create additional litigation exposure.[4]
How strong is the Xifaxan patent estate?
The estate is commercially strong but not unassailable.
Its principal strengths are:
- Multiple claim categories rather than a single compound patent.
- Protection covering both product characteristics and approved uses.
- A branded product with large recurring revenue, supporting extensive litigation.
- A formulation that may be difficult to reproduce without infringing or triggering regulatory disputes.
- A demonstrated ability to delay a Paragraph IV challenger through appellate litigation.
Its principal weaknesses are:
- Rifaximin is an established small molecule, so the basic active ingredient is not protected like a new chemical entity.
- Generic manufacturers can design around individual formulation claims.
- Obviousness and written-description challenges remain available.
- Method-of-use patents may be less effective where a generic label omits a protected indication but physicians prescribe the product off-label.
- Patent expiration creates a concentrated post-2029 price and volume risk.
What is the Orange Book status of Xifaxan?
Xifaxan is listed in the FDA Orange Book as a prescription drug with multiple strengths and approved indications. The listings identify patents and associated exclusivity information that ANDA applicants must address.
An ANDA applicant may submit:
- Paragraph I certification, asserting no patent is listed.
- Paragraph II certification, asserting the patent has expired.
- Paragraph III certification, accepting approval after patent expiration.
- Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed.
Rifaximin generic applicants have used Paragraph IV litigation to challenge Xifaxan protection. A Paragraph IV filing can trigger a patent lawsuit within 45 days. That lawsuit can delay FDA approval for up to 30 months, subject to court decisions and statutory exceptions.[5]
The FDA’s Orange Book listing is central to timing analysis, but it does not by itself determine whether a generic will launch. Court judgments, settlements, later-issued patents, and the terms of any license determine the practical outcome.
Which companies are challenging rifaximin patents?
Norwich Pharmaceuticals has been the most prominent public Paragraph IV challenger to Xifaxan. Its proposed product triggered litigation with Bausch and related patent holders.
Other potential challengers could include major generic companies such as Teva, Viatris, Sandoz, Sun Pharma, Dr. Reddy’s, Zydus, and Amneal. A company may challenge the patents, wait for the litigation outcome, pursue a settlement, or launch after patent expiration. Public evidence of an approved, commercially launched generic is distinct from the existence of an ANDA or patent challenge.
As of the relevant public FDA and court record, the key market fact is that Xifaxan has not faced broad, fully commercialized generic substitution comparable to mature oral solid products with expired compound patents.
What formulations of rifaximin are protected?
Formulation protection is important because rifaximin’s commercial value depends on a specific low-absorption oral product rather than the active ingredient alone.
Relevant formulation issues include:
- Tablet composition.
- Rifaximin polymorphic form.
- Particle size and solid-state characteristics.
- Dissolution profile.
- Excipients and manufacturing process.
- Stability and bioavailability characteristics.
- Dose-specific performance for 200 mg and 550 mg tablets.
These features can create regulatory and manufacturing barriers even when the underlying chemical entity is old. A generic manufacturer must show pharmaceutical equivalence and bioequivalence, while also avoiding infringement of valid formulation claims.
The 550 mg product is commercially more important than the 200 mg travelers’ diarrhea product because it supports the hepatic encephalopathy and IBS-D franchises. A generic applicant that targets only one strength or indication may achieve a different regulatory and litigation profile from an applicant seeking broad substitution.
Is rifaximin exposed to biosimilar competition?
No. Rifaximin is a small-molecule drug, not a biologic. It is subject to the abbreviated new drug application pathway rather than the biosimilar pathway under the Public Health Service Act.
The relevant competitive risks are:
- ANDA approval.
- Paragraph IV patent challenges.
- Authorized-generic launch.
- Formulation redesign.
- Off-label substitution.
- International generic supply entering regulated markets through approved channels.
Biosimilar development is therefore not relevant to rifaximin’s U.S. exclusivity analysis.
What generic launch scenarios exist for rifaximin?
Scenario 1: No launch before 2029
This is the base-case commercial scenario if Bausch continues to prevail in patent litigation and no settlement permits an earlier entry. Under this outcome, Xifaxan retains high pricing and substantial gross margin through the remaining patent term.
Scenario 2: At-risk launch
A generic company could launch before final resolution of all patent claims. That strategy would expose the company to damages, an injunction, or a negotiated withdrawal. At-risk entry is less likely where the patent holder has obtained favorable appellate rulings and the product has substantial sales.
Scenario 3: Licensed settlement entry
Bausch could settle with a generic company and grant a defined entry date before or at patent expiration. Settlement economics could include a royalty, supply agreement, or delayed launch. No settlement should be assumed without a public court filing or company disclosure.
Scenario 4: Narrow indication entry
A generic could attempt to omit a patented method of use from its label while pursuing approval for an unprotected indication. This approach depends on the scope of the listed patents, labeling requirements, and whether the remaining indications support a commercially viable product.
Scenario 5: Multiple-generic erosion after expiry
Once several ANDAs are approved, the product could experience rapid price erosion. Oral solid generics often lose significant share when pharmacy substitution becomes available, although the magnitude depends on the number of entrants, payer controls, supply reliability, and physician prescribing.
What is the financial exposure to Bausch Health?
Xifaxan is one of Bausch Health’s most important products because it combines high revenue with recurring use and relatively strong pricing. A generic launch would affect:
- Salix revenue.
- Consolidated Bausch Health revenue.
- Adjusted EBITDA.
- Debt-service capacity.
- Cash available for acquisitions and business development.
- Valuation of the Salix franchise.
- Potential separation or refinancing strategies involving Bausch’s businesses.
The financial impact would likely be nonlinear. A single authorized generic may reduce price but preserve significant volume. Several independent generics could produce faster price compression and a larger shift in payer behavior.
A 20% decline in a $1.2 billion annual product would represent roughly $240 million in lost annual revenue before offsetting effects. A 50% decline would represent approximately $600 million. The earnings impact would be greater than the revenue impact if most lost sales carry high incremental margins.
How does rifaximin compare with competing gastrointestinal drugs?
| Product or therapy |
Company or source |
Primary use |
Competition profile |
| Xifaxan |
Bausch/Salix |
Hepatic encephalopathy, IBS-D |
Patent-protected branded product |
| Lactulose |
Multiple manufacturers |
Hepatic encephalopathy |
Low-cost, generic, less convenient |
| Viberzi |
AbbVie |
IBS-D |
Branded alternative with safety and prescribing limitations |
| Lotronex |
Sebela Pharmaceuticals |
Severe IBS-D in selected patients |
Restricted use and narrower population |
| Loperamide |
Multiple manufacturers |
Diarrhea symptom control |
OTC, inexpensive, not disease-modifying |
| Antibiotic alternatives |
Multiple manufacturers |
Travelers’ diarrhea |
Different resistance and absorption profiles |
Rifaximin’s strongest competitive advantage is in hepatic encephalopathy prevention, where lactulose remains important but is often used with rifaximin or as a less expensive alternative. In IBS-D, competition is more fragmented and includes prescription, OTC, dietary, and behavioral approaches.
What licensing deals and ownership arrangements affect rifaximin?
Rifaximin was developed from the rifamycin class and has been associated with Alfa Wassermann, now Alfasigma, outside the U.S. Salix obtained U.S. commercial rights and built the product franchise before its acquisition by Valeant Pharmaceuticals, now Bausch Health.[6]
The commercial structure has two important consequences:
- Bausch controls the U.S. revenue stream and U.S. patent strategy through Salix.
- International rights and manufacturing relationships may involve Alfasigma or other partners, creating geographic differences in ownership, supply, and patent enforcement.
U.S. market economics should therefore not be inferred directly from European or other international markets, where approval status, pricing, reimbursement, and patent rights differ.
What is the long-term market outlook for rifaximin?
Rifaximin is likely to remain a high-value branded gastrointestinal product through the late 2020s. The most important near-term growth levers are price realization, hepatic encephalopathy patient persistence, IBS-D retreatment, and improved diagnosis.
The largest strategic risk is concentrated generic entry after the principal patent barrier ends. Bausch may seek to extend the franchise through:
- New formulations.
- Additional indications.
- Combination products.
- Licensing or supply agreements.
- Authorized-generic control.
- Lifecycle management in hepatic encephalopathy and IBS-D.
The commercial outlook after 2029 will depend less on clinical differentiation and more on the number and timing of approved competitors.
Key Takeaways
- Xifaxan is rifaximin’s dominant U.S. commercial product and generated approximately $1.2 billion in annual revenue in 2023.
- Hepatic encephalopathy is the core recurring-use market; IBS-D is the main additional growth segment.
- Xifaxan is protected by a multi-layer patent estate covering composition, polymorph, formulation, and methods of use.
- Norwich Pharmaceuticals’ Paragraph IV challenge was the principal public generic threat, and 2023 Federal Circuit litigation preserved major barriers to near-term entry.
- The leading generic-entry window is approximately 2029, subject to patent litigation, settlements, and later-issued rights.
- Rifaximin is a small molecule and has no biosimilar exposure.
- Generic entry could materially reduce Bausch Health revenue, EBITDA, and Salix franchise value.
- Post-expiry erosion will depend on the number of approved ANDAs and whether an authorized generic launches.
FAQs
What is the expected generic price impact for rifaximin?
Multiple generic entrants could cause substantial price erosion, while a single authorized generic may produce a smaller decline. The outcome will depend on pharmacy substitution, payer contracting, and supply capacity.
Is rifaximin approved for small intestinal bacterial overgrowth?
No. Rifaximin is not specifically FDA-approved for small intestinal bacterial overgrowth, although clinicians may prescribe it off-label in selected cases.
Does lactulose replace rifaximin for hepatic encephalopathy?
Lactulose is an important lower-cost therapy and may be used alone or with rifaximin. Rifaximin has a distinct role in reducing recurrence in patients with hepatic encephalopathy.
Can a generic launch for IBS-D occur without approval for hepatic encephalopathy?
Potentially, depending on the ANDA’s labeling strategy and the patents listed for each indication. The commercial value of a narrow indication would be lower than a fully substitutable 550 mg product.
Why is rifaximin difficult to copy despite being an old antibiotic?
The active ingredient is old, but commercial replication involves the correct polymorph, formulation, dissolution characteristics, manufacturing process, regulatory evidence, and patent clearance.
References
- Bausch Health Companies Inc. (2024). 2023 annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Patent and Trademark Office. (2008). U.S. Patent No. 8,309,569: Rifaximin compositions and methods.
- United States Court of Appeals for the Federal Circuit. (2023). Bausch Health Ireland Ltd. v. Norwich Pharmaceuticals Inc.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023). Guidance for industry: 180-day exclusivity for generic drug products.
- Salix Pharmaceuticals. (2015). Xifaxan prescribing information and product history.
